ProfileGDS5678 / 1458510_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 81% 83% 84% 80% 79% 82% 83% 80% 78% 81% 80% 81% 81% 82% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.6987581
GSM967853U87-EV human glioblastoma xenograft - Control 26.15783
GSM967854U87-EV human glioblastoma xenograft - Control 36.2033384
GSM967855U87-EV human glioblastoma xenograft - Control 45.7464580
GSM967856U87-EV human glioblastoma xenograft - Control 55.5656779
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.7985682
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.9594283
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.6803980
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.4307578
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.8598581
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.6321280
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.8509881
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.8487481
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.9256282